Similar companies
Income Statement (GBP)
| Q2 '24 | QoQ | |
|---|---|---|
| Gross Profit | -1.1M | 47.7% |
| Cost of Revenue | 1.1M | 47.7% |
| Operating expense | 2.1M | 40.3% |
| Net Income | -2M | 39.1% |
| EBITDA | -2M | 40.4% |
Balance Sheet (GBP)
| Q2 '24 | QoQ | |
|---|---|---|
| Total Assets | 6.9M | 5.4% |
| Total Liabilities | 4.9M | 21.3% |
| Total Equity | 2M | 85.5% |
| Shares Outstanding | 99M | 54.8% |
Cash Flow (GBP)
| Q2 '24 | QoQ | |
|---|---|---|
| Cash from operations | -2.7M | 13.5% |
| Cash from investing | -30,000 | 435.1% |
| Cash from financing | 2.8M | 198.8% |
Financial Highlights for TC BioPharm in Q2 '24
Gross Profit stood at -1.1M, marking a 47.7% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 1.1M, a -47.7% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 2.1M, showing a -40.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -2M, showing a 39.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -2M, showing a 40.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
